ANNA Home Page
ANNA CE Link
HDCN Home Page
HDCN Registration Link

If you dont have an Acrobat Reader installed on your computer, you may download it for free from the link below:


Smoking Cessation Therapy Considerations for Patients with Chronic Kidney Disease
(Vol 35/No. 4. On-line test expires: 08/20/2010)
To receive continuing education credit, you must read the information in this article and take an on-line post test and fill out an on-line program evaluation form. The certificate will then be generated for you as a .pdf file which you can print out locally on your computer.

CE Certification by ANNA requires a handling charge that must be paid by credit card. Pricing information is available by clicking on the "Post-Test Evaluation" link below.
  DOWNLOAD TEST ARTICLE
Please download and print the PDF file below:
  AUTHOR
Harold J. Manley, PharmD, FASN, FCCP, BCPS
 Harold J. Manley, PharmD, FASN, FCCP, BCPS, is Director of Clinical Pharmacy, DaVita VillageHealth Disease Management, Vernon Hill, IL, and a Member, the Albany Nephrology Pharmacy Group (ANephRx).
Nicole M. Stack, PharmD
 Nicole M. Stack, PharmD, is an Assistant Professor, Albany College of Pharmacy, Albany, NY.
  OUTLINE

Cigarette smoking is a readily modifiable cardiovascular and chronic kidney disease (CKD) risk factor. Smoking cessation aids include nicotine replacement therapy (NRT), bupropion, and varenicline. Several reports suggest that patients with CKD who use tobacco products be encouraged to stop; however, very little is offered to the healthcare provider as to how to successfully prescribe and monitor smoking cessation therapy for this patient population. This article reviews NRT, bupropion, and varenicline pharmacokinetics and dosing literature for patients with CKD. Evidence for the benefit of smoking cessation in patients with CKD is also reviewed.
  GET YOUR CE CERTIFICATE
Take on-line Quiz:
  CE RELATED INFORMATION
This offering for 1.9 contact hours is being provided by the American Nephrology Nurses’ Association (ANNA), which is accredited as a provider and approver of continuing education in nursing by the American Nurses’ Credentialing Center-Commission on Accreditation (ANCCCOA). This educational activity is approved by most states and specialty organizations that recognize the ANCC-COA accreditation process. ANNA is an approved provider of continuing education in nursing by the California Board of Registered Nursing, BRN Provider No. 00910; and the Kansas State Board of Nursing, Provider No. LT0148-0738. This offering is accepted for RN and LPN relicensure in Kansas.

  EDUCATIONAL OBJECTIVES

Goal:
To increase awareness about smoking cessation therapy for patients with chronic kidney disease.

 Objectives:
1. Explain how nicotine replacement therapy, bupropion, and varenicline are used as methods of smoking cessation therapy.
2. Describe the pharmacokinetics of bupropion and varenicline.
3. Discuss smoking cessation outcomes in patients with CKD.

AUTHOR DISCLOSURE STATEMENT

Harold J. Manley has no conflicts of interest to disclose.
Nicole M. Stack has no conflicts of interest to disclose.

 ANNA and HDCN CE POLICY STATEMENTS

The CE policy and disclosure statements of the American Nephrology Nurses' Association are given in detail on the Symposium Home Page. The CE policy statements of HDCN are listed on this page.